NOTCH1 and Mobius syndrome: By inference, therefore, it may be proposed that co-targeting of Notch and PDGFR signaling should constitute a more promising effective therapeutic modality for MB, particularly since previous data show that Notch1 inhibition may not be sufficiently robust to achieve tumor control in a small cohort of pre-treated, relapsed MBs [84].